The University of Southampton
University of Southampton Institutional Repository

SQ house dust mite sublingual immunotherapy tablet in children with allergic asthma: a randomised phase III trial

SQ house dust mite sublingual immunotherapy tablet in children with allergic asthma: a randomised phase III trial
SQ house dust mite sublingual immunotherapy tablet in children with allergic asthma: a randomised phase III trial

Background: in children, house dust mite (HDM) sensitisation is a contributing factor for developing allergic asthma. HDM allergen immunotherapy has demonstrated efficacy and safety in adults with allergic asthma; however, evidence for its use in children is limited. MT-11 evaluated the efficacy and safety of the SQ HDM sublingual immunotherapy (SLIT) tablet in children (5–17 years) with HDM allergic asthma. 

Methods: this phase III, randomised, double-blind, placebo-controlled trial randomised 533 children with a recent history of asthma exacerbations, despite treatment with inhaled corticosteroids and/or long-acting beta-agonists, to daily treatment with SQ HDM SLIT-tablet or placebo for 24–30 months. The primary endpoint was the annualised rate of clinically relevant asthma exacerbations. Adverse events (AEs) were reported throughout the trial. 

Results: the rate ratio for the annualised rate of clinically relevant asthma exacerbations was 0.89 (95% CI: 0.60, 1.31), in favour of the SQ HDM-SLIT tablet; superiority over placebo was not established. Most treatment-related AEs (TRAEs) were of mild or moderate severity, and few subjects discontinued due to TRAEs (< 2%). The most common TRAEs were local application site reactions (oral pruritus, throat irritation, ear pruritus, and upper abdominal pain). There was no increased incidence of asthma-related events, and no anaphylaxis or adrenaline use in the SQ HDM SLIT-tablet group. 

Conclusion: as a result of the coronavirus disease 2019 pandemic, asthma exacerbation rates were much lower than expected, contributing to the primary endpoint not being met. The SQ HDM SLIT-tablet was well tolerated in a paediatric population with inadequately controlled HDM allergic asthma. Trial Registration: Clinicaltrials.gov identifier: NCT03654976; EudraCT number: 2016-004363-39.

allergen immunotherapy, allergic asthma, children, house dust mite, sublingual immunotherapy
0105-4538
Roberts, Graham
ea00db4e-84e7-4b39-8273-9b71dbd7e2f3
Just, Jocelyne
ae1fd282-3151-40c8-810b-5d57988e305b
Nolte, Hendrik
1f5625c7-8379-4398-bf26-51eb194edc5c
Hels, Ole Holm
14f248e4-fe2d-4f78-9a5c-5345e79caaf5
Emeryk, Andrzej
314abef7-2651-48a8-9303-82f906889b58
Vidal, Carmen
6728932c-8094-40a8-87d5-8e27d7781722
Roberts, Graham
ea00db4e-84e7-4b39-8273-9b71dbd7e2f3
Just, Jocelyne
ae1fd282-3151-40c8-810b-5d57988e305b
Nolte, Hendrik
1f5625c7-8379-4398-bf26-51eb194edc5c
Hels, Ole Holm
14f248e4-fe2d-4f78-9a5c-5345e79caaf5
Emeryk, Andrzej
314abef7-2651-48a8-9303-82f906889b58
Vidal, Carmen
6728932c-8094-40a8-87d5-8e27d7781722

Roberts, Graham, Just, Jocelyne, Nolte, Hendrik, Hels, Ole Holm, Emeryk, Andrzej and Vidal, Carmen (2025) SQ house dust mite sublingual immunotherapy tablet in children with allergic asthma: a randomised phase III trial. Allergy. (doi:10.1111/all.70073).

Record type: Article

Abstract

Background: in children, house dust mite (HDM) sensitisation is a contributing factor for developing allergic asthma. HDM allergen immunotherapy has demonstrated efficacy and safety in adults with allergic asthma; however, evidence for its use in children is limited. MT-11 evaluated the efficacy and safety of the SQ HDM sublingual immunotherapy (SLIT) tablet in children (5–17 years) with HDM allergic asthma. 

Methods: this phase III, randomised, double-blind, placebo-controlled trial randomised 533 children with a recent history of asthma exacerbations, despite treatment with inhaled corticosteroids and/or long-acting beta-agonists, to daily treatment with SQ HDM SLIT-tablet or placebo for 24–30 months. The primary endpoint was the annualised rate of clinically relevant asthma exacerbations. Adverse events (AEs) were reported throughout the trial. 

Results: the rate ratio for the annualised rate of clinically relevant asthma exacerbations was 0.89 (95% CI: 0.60, 1.31), in favour of the SQ HDM-SLIT tablet; superiority over placebo was not established. Most treatment-related AEs (TRAEs) were of mild or moderate severity, and few subjects discontinued due to TRAEs (< 2%). The most common TRAEs were local application site reactions (oral pruritus, throat irritation, ear pruritus, and upper abdominal pain). There was no increased incidence of asthma-related events, and no anaphylaxis or adrenaline use in the SQ HDM SLIT-tablet group. 

Conclusion: as a result of the coronavirus disease 2019 pandemic, asthma exacerbation rates were much lower than expected, contributing to the primary endpoint not being met. The SQ HDM SLIT-tablet was well tolerated in a paediatric population with inadequately controlled HDM allergic asthma. Trial Registration: Clinicaltrials.gov identifier: NCT03654976; EudraCT number: 2016-004363-39.

Text
Allergy - 2025 - Roberts - SQ House Dust Mite Sublingual Immunotherapy Tablet in Children With Allergic Asthma A - Version of Record
Available under License Creative Commons Attribution.
Download (516kB)

More information

Accepted/In Press date: 15 August 2025
e-pub ahead of print date: 9 October 2025
Keywords: allergen immunotherapy, allergic asthma, children, house dust mite, sublingual immunotherapy

Identifiers

Local EPrints ID: 506772
URI: http://eprints.soton.ac.uk/id/eprint/506772
ISSN: 0105-4538
PURE UUID: 7d073a19-d4e4-49ed-b70b-37ae424a454a
ORCID for Graham Roberts: ORCID iD orcid.org/0000-0003-2252-1248

Catalogue record

Date deposited: 18 Nov 2025 17:39
Last modified: 19 Nov 2025 02:40

Export record

Altmetrics

Contributors

Author: Graham Roberts ORCID iD
Author: Jocelyne Just
Author: Hendrik Nolte
Author: Ole Holm Hels
Author: Andrzej Emeryk
Author: Carmen Vidal

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×